248 related articles for article (PubMed ID: 29421999)
1. DNA Double Strand Break Repair - Related Synthetic Lethality.
Toma M; Skorski T; Sliwinski T
Curr Med Chem; 2019; 26(8):1446-1482. PubMed ID: 29421999
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Lethality Targeting Polθ.
Drzewiecka M; Barszczewska-Pietraszek G; Czarny P; Skorski T; Śliwiński T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741863
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
4. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
5. Synthetic lethal interaction between oxidative stress response and DNA damage repair in the budding yeast and its application to targeted anticancer therapy.
Choi JE; Chung WH
J Microbiol; 2019 Jan; 57(1):9-17. PubMed ID: 30594981
[TBL] [Abstract][Full Text] [Related]
6. Targeting cancer-specific synthetic lethality in double-strand DNA break repair.
Moeller BJ; Pasqualini R; Arap W
Cell Cycle; 2009 Jun; 8(12):1872-6. PubMed ID: 19440052
[TBL] [Abstract][Full Text] [Related]
7. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
8. Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy.
Schrempf A; Slyskova J; Loizou JI
Trends Cancer; 2021 Feb; 7(2):98-111. PubMed ID: 33109489
[TBL] [Abstract][Full Text] [Related]
9. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.
Stachelek GC; Peterson-Roth E; Liu Y; Fernandez RJ; Pike LR; Qian JM; Abriola L; Hoyer D; Hungerford W; Merkel J; Glazer PM
Mol Cancer Res; 2015 Oct; 13(10):1389-97. PubMed ID: 26116172
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA double-strand break signalling and repair: recent advances in cancer therapy.
Hühn D; Bolck HA; Sartori AA
Swiss Med Wkly; 2013; 143():w13837. PubMed ID: 23897299
[TBL] [Abstract][Full Text] [Related]
11. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
12. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethality on drug discovery: an update on cancer therapy.
Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
15. DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics.
Kopa P; Macieja A; Galita G; Witczak ZJ; Poplawski T
Curr Med Chem; 2019; 26(8):1483-1493. PubMed ID: 29446719
[TBL] [Abstract][Full Text] [Related]
16. The power and the promise of synthetic lethality for clinical application in cancer treatment.
Liu QW; Yang ZW; Tang QH; Wang WE; Chu DS; Ji JF; Fan QY; Jiang H; Yang QX; Zhang H; Liu XY; Xu XS; Wang XF; Liu JB; Fu D; Tao K; Yu H
Biomed Pharmacother; 2024 Mar; 172():116288. PubMed ID: 38377739
[TBL] [Abstract][Full Text] [Related]
17. DNA double-strand break repair in cancer: A path to achieving precision medicine.
Gillyard T; Davis J
Int Rev Cell Mol Biol; 2021; 364():111-137. PubMed ID: 34507781
[TBL] [Abstract][Full Text] [Related]
18. Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review.
Watanabe K; Seki N
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255825
[TBL] [Abstract][Full Text] [Related]
19. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
20. Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer.
O'Kane GM; Connor AA; Gallinger S
Trends Mol Med; 2017 Dec; 23(12):1121-1137. PubMed ID: 29133135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
